The DOI matches its Crossref record.
U.S. Food and Drug Administration Approval: Vismodegib for Recurrent, Locally Advanced, or Metastatic Basal Cell Carcinoma
Abstract
The data and regulatory considerations leading to the U.S. Food and Drug Administration (FDA) January 30, 2012 approval of Erivedge (vismodegib) capsules for the treatment of patients with recurrent, locally advanced, or metastatic basal cell carcinoma (BCC) are described. The FDA's approval decision was based primarily on the results observed in a single-arm, parallel cohort, international trial of vismodegib, administered orally at 150 mg daily until disease progression, in patients with pathologically confirmed, recurrent, locally advanced basal cell carcinoma (laBCC) or metastatic basal cell carcinoma (mBCC). An independent review committee confirmed an overall response rate (ORR) of 30.3% [95% confidence interval (CI): 15.6–48.2] in 33 patients with mBCC and an ORR of 42.9% (95% CI: 30.5–56.0) in 63 patients with laBCC; median response durations were 7.6 months and 7.6 months for patients with mBCC and laBCC, respectively. The most common adverse reactions were muscle spasms, alopecia, dysgeusia, weight loss, fatigue, nausea, diarrhea, decreased appetite, constipation, cough, arthralgias, vomiting, headache, ageusia, insomnia, and upper respiratory tract infection. Animal toxicology studies confirmed that vismodegib is a potent teratogenic agent. Approval was based on durable objective tumor responses supported by knowledge of the pathologic role of Hedgehog signaling in BCC and acceptable toxicity in a population without effective alternative therapies. Clin Cancer Res; 19(9); 2289–93. ©2013 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Zhou, H.-M., Zhang, J.-G., Zhang, X., & Li, Q. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00430-1 · Cited by 472
Smoothened Variants Explain the Majority of Drug Resistance in Basal Cell Carcinoma
Atwood, S. X., Sarin, K. Y., Whitson, R. J., Li, J. R., Kim, G., Rezaee, M., Ally, M. S., Kim, J., Yao, C., Chang, A. L. S., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.02.002 · Cited by 404
Indian Hedgehog links obesity to development of hepatocellular carcinoma
Chong, Y. C., Lim, T. E., Fu, Y., Shin, E. M., Tergaonkar, V., & Han, W. (2019) · Oncogene · doi:10.1038/s41388-018-0585-5 · Cited by 29
Metadata
- Authors
- Axelson, M., Liu, K., Jiang, X., He, K., Wang, J., Zhao, H., Kufrin, D., Palmby, T., Dong, Z., Russell, A. M., Miksinski, S., Keegan, P., & Pazdur, R.
- Venue
- Clinical Cancer Research
- Published
- 2013-04-30
- Volume
- 19
- Issue
- 9
- Pages
- 2289-2293
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2163036693
- Cited by
- 185
- References
- 0
- FWCI
- 5.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: U.S. Food and Drug Administration Approval: Vismodegib for Recurrent, Locally Advanced, or Metastatic Basal Cell Carcinoma. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-12-1956
- The paper
- Axelson, M., Liu, K., Jiang, X., He, K., Wang, J., Zhao, H., Kufrin, D., Palmby, T., Dong, Z., Russell, A. M., Miksinski, S., Keegan, P., & Pazdur, R. (2013). U.S. Food and Drug Administration Approval: Vismodegib for Recurrent, Locally Advanced, or Metastatic Basal Cell Carcinoma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-12-1956
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.